Search fresh public links, source activity, and ready-to-use post angles for Celea Therapeutics.
Fresh curated links around Celea Therapeutics are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
PureTech Health spinout Celea Therapeutics will apply the financing toward a Phase 3 test of its idiopathic pulmonary (IPF) drug, deupirfenidone. The pivotal study will test the or...
Vera Therapeutics Anonymous (not verified) Wed, 07/01/2026 - 06:05 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
Cellares plans to translate the manufacturing of SonomaBio’s SBT-77-7101 onto its Cell Shuttle and automate in-process and release testing through the Cell Q quality control syste...
All the technologies featured at BioTrinity 2026 have the goal of addressing unmet needs in areas like chronic wounds and ophthalmic diseases, and the associated companies highligh...
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon fol...
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
As TSC-101 is advanced toward a pivotal trial, which is expected to begin later this year, Cellares’ manufacturing platform is being evaluated as a scalable and economical path to...
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hop...
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
Biotech Graphics: Illustrating Synthetic Cells Client: Cell Care Therapeutics Industry: Biotech CEO: Nicolas Sohl For: Pitch Decks, Corporate website, Social Media Goal and Challen...
iRegene Therapeutics completed a 210 million yuan ($29 million) Series C1 financing round to advance its AI-driven chemical induction platform for universal cell therapies targetin...
Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...
Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments.
Circio and Tcelltech will combine Circio's circVec circular RNA expression technology with Tcelltech's non-viral, high-cargo capacity nanoSMAR vector platform and evaluate the comb...
Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnolo...
ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.